AS900672-Enriched in Ovulation Induction
A Phase II, Multicentre, Randomised, Assessor-blinded, Active-comparator, Parallel-group Dose Finding Trial to Evaluate AS900672-enriched Versus Follitropin Alfa (GONAL-f®) in Oligo-anovulatory Infertile Women Undergoing Ovulation Induction (OI)
Sponsor: Merck KGaA, Darmstadt, Germany
Terminated
The study was terminated after Merck Serono had taken the decision not to pursue the development of AS900672-enriched in ovulation induction
Other terminated trials from Merck KGaA, Darmstadt, Germany
Other Ovulation Induction trials with similar outcome
Listed as NCT00553514, this PHASE2 trial focuses on Ovulation Induction and remains terminated or withdrawn. Sponsored by Merck KGaA, Darmstadt, Germany, it has been updated 10 times since 2007, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Jan 2019 — Nov 2020 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE2
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
For direct contact, visit the study record on ClinicalTrials.gov .